Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) shot up 1.6% during trading on Wednesday . The stock traded as high as $1.91 and last traded at $1.90. 378,180 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 1,476,877 shares. The stock had previously closed at $1.87.
Tharimmune Price Performance
The stock has a market capitalization of $74.33 million, a price-to-earnings ratio of -0.49 and a beta of 1.43. The stock’s 50 day simple moving average is $2.48 and its 200-day simple moving average is $3.34.
Hedge Funds Weigh In On Tharimmune
Institutional investors have recently made changes to their positions in the business. Clear Street Group Inc. acquired a new stake in Tharimmune in the 4th quarter valued at approximately $5,066,000. Drucker Wealth 3.0 LLC boosted its position in shares of Tharimmune by 150.0% in the fourth quarter. Drucker Wealth 3.0 LLC now owns 25,337 shares of the company’s stock valued at $77,000 after acquiring an additional 15,202 shares during the period. Feynman Point Asset Management LLC bought a new stake in shares of Tharimmune in the fourth quarter valued at approximately $1,314,000. Blair William & Co. IL acquired a new stake in shares of Tharimmune in the fourth quarter worth $831,000. Finally, Marshall Wace LLP acquired a new stake in shares of Tharimmune in the fourth quarter worth $1,030,000. 1.16% of the stock is currently owned by institutional investors.
About Tharimmune
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.
Further Reading
- Five stocks we like better than Tharimmune
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
